METABOLIC GENE POLYMORPHISMS
ASSOCIATED WITH ATOPIC BRONCHIAL ASTHMA
Ivaschenko TE1, Sideleva OG1, Zelenina LA2, Antonova EA2,
Ostankova JV1, Aseev MV1, Baranov VS1
*Corresponding Author: Professor Dr. Vladislav S. Baranov, Ott’s Institute of Obstetrics/Gynecology, Russian Academy of Medical Sciences, Mendeleevskaya line 3, 199034 St. Petersburg, Russia; Tel/Fax: +07(812) 3280487 E-mail: baranov@vb2475.spb.edu page: 23
|
MATERIALS AND METHODS
Patients and controls. The study group comprised 43 children (age range 10.2 ± 3.1 years) selected on the basis of ABA, patients from the Institute of Pulmonology and St. Olga’s Hospital in St. Petersburg, Russia. The characteristics of the recruited subjects are summarized in Table 1. The control group consisted of 51 healthy, unrelated subjects from St. Petersburg. Blood spots, collected on filter paper from each patient, were used directly for polymerase chain reaction (PCR), with or without prior DNA extraction.
PCR and PCR-RFLP (restriction fragment length polymorphism) analyses. GSTM1 and GSTT1 gene polymorphism analyses were carried out, with slight modifications as described elsewhere [10]. Co-amplification of a 192 bp DNA fragment of the CYPA1 gene (A1R: 5'-GAACTGCCACTTCAGCTGTCT-3'; A1F: 5'-GAAAGA CTCCCAGCGGTCA-3') was used throughout the study as a standard positive internal control for precise identification of the GSTM10/0 and GSTT10/0 genotypes. These were identified by the absence of the normal 271 bp DNA fragment typical for the GSTM1 active genotypes (GSTM1+/+ or GSTM1+/0), or a 315 bp DNA fragment typical for the GSTT1 active genotypes (GSTT1+/+ or GSTT1+/0).
A single PCR amplification was run with the following primers (GSTM1 F: 5'-GAACTCCCTGAAAA GCTAAAGC -3'; GSTM1 R: 5'-GTTGGGCTCAAATAT ACGGTGG-3'; and GST T1 F: 5'-TTCCTTACTGGTCC TCACATCTC -3'; GST T1 R: 5'-TCACCGGATCATGG CCAGCA-3'; 15 nM each in 25 mL amplification mixture plus 67 mM Tris-HCl (pH 8.8), 16.6 mM ammonium sulphate, 6.7 mM MgCl2, 6.7 mM EDTA, 10 mM mercaptoethanol, 170 mg BSA, 1.0 mM of each dNTP, 1 U of Taq polymerase (Bion, Moscow, Russia). Denaturation (7 minutes at 94°C) was followed by 32 cycles of amplification: 1 minute at 94°C, 1 minute at 53°C, 1 minute 20 seconds at 72°C, and final extension for 7 minutes at 72°C. The products were subjected to electrophoresis on a 7% polyacrylamide gel, stained with ethidium bromide and visualized under UV light.
Three polymorphic alleles of the GSTP1 gene were identified: GSTP1*A (wild type Ile105/Ala114), GSTP1*B (Val105/Ala114), and GSTP1*C (Val105/ Val114) [11]. The Ile105/Val105 gene polymorphism in GSTP1 was examined after PCR amplification through the use of primers to exon 5 (GST p1 F: 5'-CTCTATGGGAA GGACCAGCAGGAG-3' and GST p2 R: 5'-CAAGCCAC CTGAGGGGTAAGG-3'). The PCR conditions were as follows: denaturation (7 minutes at 94°C) was followed by 32 cycles of amplification: 1 minute at 94°C, 1 minute at 60°C, 1 minute 20 seconds at 72°C, and final extension for 7 minutes at 72°C. The resulting 192 bp fragment was digested with BsoMoI1 to identify the A/G transition at nucleotied 1313. The undigested PCR product has the molecular length of 192 bp. The amplification product of the Val/Val type is cut into 80 and 112 bp fragments, respectively.
A PCR-based genotyping test was subsequently developed for the detection of the Ala114/Val114 gene polymorphism. This test used a reverse PCR primer with a 1 bp mismatch (GST p4 R: 5'-GCCTTCACATAGTCATCCT TGCGC-3' from exon 6, and a forward primer (GST p3 F: 5'-GTTGTGGGGAGCAAGCAGAGG-3') from intron 5. The mismatched primer introduced a BstFN1 site in the Ala114 allele but not in the Val114 allele.
The PCR conditions were as follows: denaturation (7 minutes at 94°C) was followed by 32 cycles of amplification: 1 minute at 94°C, 1 minute at 60°C, 1 minute 20 seconds at 72°C, with a final extension at 72°C for 7 minutes. The resulting 142 bp products were digested overnight with 10 units of BstFN1 at 37°C, and the fragments were separated on a 7% polyacrylamide gel. Samples containing the Ala114 allele produced 121 and 25 bp fragments, respectively, after BstFN1 digestion, whereas the 142 bp product generated from the Val114 allele remained uncut.
Statistical analyses. A chi-square test (c2) was used for comparison of different polymorphic genotype distribution and their association with ABA. Statistical analyses were performed using Microsoft Excel (Microsoft Office 97). OR was estimated by the standard formula, OR = a/b x d/c, where a and b are the number of patients with or without the mutant genotype, respectively; c and d are the number of people in the control group with or without the mutant genotype, respectively. OR is specified with 95% confidential interval. Borders of a confidential interval were calculated under the following formulas: ORmin= OR(1-1,96/ ?_2) ORmax= OR(1+1,96/ v_2).
Table 1. Clinical parameters of the recruited subjects
|
n |
% |
Males |
31 |
72 |
Females |
12 |
28 |
Age range |
10.2 ±3.1 |
– |
Family history of disease |
23 |
52 |
Atopic dermatitis |
29 |
67 |
Positive skin test |
43 |
100 |
Onset of the disease:
Before age 7 After age 7 |
3310 |
76.0 24.0 |
Course of the disease:
Severe
Moderate Mild |
16
23 4 |
37.0
54.0 9.0 |
Table 2. Distribution of GSTM1, GSTT1 and GSTP1 genotypes in ABA children with respect to age of disease onset and atopic dermatitis [% (%)]
Genotype
|
Control
|
ABA Children
|
Disease Onset
|
Atopic Dermatitis
|
|
|
|
Before Age 7 |
After Age 7 |
Yes |
No |
GSTM10/0
GSTM1+ |
45.0 (23)?
55.0 (28) |
79.0 (34)?
31.0 (9) |
72.0 (24)
28.0 (9) |
100.0 (10)
0 |
90.0 (26)‚
10.0 (3) |
57.0 (8)‚
43.0 (6) |
GSTT10/0
GSTT1+ |
20.0 (10)?
80.0 (41) |
58.0 (25)?
42.0 (18) |
55.0 (18)
45.0 (15) |
70.0 (7) 30.0 (3) |
62.0 (18)
38.0 (11) |
50.0 (7)
50.0 (7) |
GSTP1 A/A
GSTP1 A/B
GSTP1 A/C
GSTP1 B/B
GSTP1 B/C
GSTP1 C/C |
53.0 (27)
25.0 (13)
16.0 (8)
2.0 (1)
2.0 (1) 2.0 (1) |
44.0 (19)
30.0 (13)
23.0 (10)
2.0 (1)
0 0 |
46.0 (15)
21.0 (7)‚
30.0 (10)
3.0 (1)
0 0 |
40.0 (4)
60.0 (6)‚
0
0
0 0 |
41.0 (12)
31.0 (9)
24.0 (7)
3.0 (1)
0 0 |
50.0 (7)
29.0 (4)
21.0 (3)
0
0 0 |
? p<0.001.
? p<0.01.
|
|
|
|
|
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|
|